Skip to main content

Table 5 Referral patterns of patients receiving cardiotoxic chemotherapy agents from oncology clinic to cardio-oncology or cardiology clinic

From: Healthcare disparities in cardio oncology: patients receive same level of surveillance regardless of race at a safety net hospital

  Referred (N = 70) Not Referred (N = 79) P-value
Race    p = 0.66
 Black 33 (47.1%) 35 (44.3%)  
 White 21 (30.0%) 20 (25.3%)  
 Hispanic 14 (20.0%) 19 (27.9%)  
 Others 2 (2.9%) 5 (6.3%)  
Age at diagnosis (median, [IQR]) 61 (51, 68) 56 (50, 64) p = 0.55
Gender    p = 0.68
 Male 9 (12.9%) 12 (15.2%)  
 Female 61 (87.1%) 67 (84.8%)  
Insurance    p = 0.18
 Private insurance 39 (55.7%) 39 (49.4%)  
 Medicare 26 (37.1%) 25 (31.6%)  
 Medicaid 2 (2.9%) 3 (3.8%)  
 No insurance 3 (4.3%) 12 (15.2%)  
Income by ZIP code    p = 0.039
 Quartile 1 11 (15.7%) 26 (32.9%)  
 Quartile 2 17 (24.3%) 18 (22.8%)  
 Quartile 3 23 (32.9%) 15 (19.0%)  
 Quartile 4 19 (27.1%) 20 (25.3%)  
Risk factors
 HTN 52 (74.3%) 32 (40.5%) p < 0.0001
 HLD 25 (35.7%) 23 (29.1%) p = 0.39
 CAD 12 0 p = 0.0006
 Arrhythmia 11 4 p = 0.035
 DM 22 (31.4%) 17 (21.5%) p = 0.17
 Smoking 27 (38.6%) 34 (42.0%) p = 0.67
 FH 20 (28.6%) 20 (24.7%) p = 0.59
 Age > 65 20 (28.6%) 14 (17.7%) p = 0.12
Procedures
 Coronary stents 4 0 p = 0.13
 Cardiac surgery 1 0 p = 1.00
Medication pre initiation of chemotherapy
 Beta blocker 13 12 p = 0.63
 ACEI/ARB 26 19 p = 0.08
 Diuretic 5 5 p = 0.84
 Hydralazine 1 1 p = 0.93
 Nitrate 1 1 p = 0.93
 MRA 0 0 p = 1
 CCB 8 9 p = 0.99
 Antiarrhythmic 0 0 p = 1
 Aspirin 14 10 p = 0.22
 Statin 17 11 p = 0.11
Cancer type    p = 0.005
 Breast cancer 59 (84.3%) 52 (64.3%)  
 Other cancer 11 (15.7%) 29 (35.8%)  
Cancer stage    p = 0.07
 Stage 1 8 (11.4%) 4 (4.9%)  
 Stage 2 38 (54.3%) 33 (40.7%)  
 Stage 3 11 (15.7%) 18 (22.2%)  
 Stage 4 13 (18.6%) 26 (32.1%)  
Chemotherapy    p = 0.036
 Doxorubicin 22 (31.4%) 42 (51.9%)  
 Herceptin 40 (57.1%) 34 (42.0%)  
 Doxorubicin and herceptin 8 (11.4%) 5 (6.2%)  
\